Company Filing History:
Years Active: 2021
Title: The Innovative Contributions of Rajan Kumar Pal
Introduction: Rajan Kumar Pal is a noteworthy inventor hailing from Vadodara, India. With a remarkable focus on the intersection of pharmacology and molecular biology, he has made significant contributions to the field through his inventive work. His innovation addresses pressing health issues, particularly in breast cancer treatments.
Latest Patents: Rajan Kumar Pal holds a patent for a selective estrogen receptor degrader (SERD). This patent, characterized by the compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, presents a potential therapeutic avenue for diseases associated with the modulation of estrogen receptors. This includes its application in treating ER-positive breast cancer. The patent also details processes for the preparation of these compounds, demonstrating their pharmaceutically acceptable salts.
Career Highlights: Rajan is currently employed at Sun Pharma Advanced Research Company Limited, where his research and innovation have significantly impacted the pharmaceutical industry. His work is pivotal in advancing new therapeutic methods, particularly in oncology.
Collaborations: Throughout his career, Rajan has collaborated with esteemed colleagues such as Biswajit Samanta and Jayraj Dilipbhai Aradhye. Their combined efforts exemplify the spirit of teamwork in research and innovation, ultimately leading to advancements in medical treatment options.
Conclusion: Rajan Kumar Pal is an influential figure in the realm of pharmaceutical innovation, contributing valuable insights and advancements through his patent for a selective estrogen receptor degrader. His work at Sun Pharma Advanced Research Company Limited and collaboration with talented colleagues underscores his commitment to improving treatment options for diseases like breast cancer. The implications of his research will undoubtedly continue to benefit the medical community and patients alike.